Protection by catatoxic steroids against the paralysis caused by combined treatment with thyroxine and methylphenidate.
D000737:Androstenols / Q000494:pharmacology; D000818:Animals; D004357:Drug Synergism; D004958:Estradiol / Q000494:pharmacology; D005032:Ethylestrenol / Q000494:pharmacology; D005260:Female; D006801:Humans; D006914:Hydroxysteroids / Q000494:pharmacology; D006948:Hyperkinesis / Q000139:chemically induced; D007664:Ketosteroids / Q000494:pharmacology; D008774:Methylphenidate / Q000037:antagonists & inhibitors*; D009650:Norpregnanes / Q000494:pharmacology; D010243:Paralysis / Q000139:chemically induced*; D010634:Phenobarbital / Q000494:pharmacology; D010672:Phenytoin / Q000494:pharmacology; D011239:Prednisolone / Q000494:pharmacology; D011285:Pregnenolone Carbonitrile / Q000494:pharmacology; D011374:Progesterone / Q000494:pharmacology; D011422:Propionates / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D013148:Spironolactone / Q000494:pharmacology; D013256:Steroids / Q000494:pharmacology*; D013974:Thyroxine / Q000037:antagonists & inhibitors* / Q000494:pharmacology
D000737:Androstenols; D006914:Hydroxysteroids; D007664:Ketosteroids; D009650:Norpregnanes; D011422:Propionates; D013256:Steroids; D011285:Pregnenolone Carbonitrile; D008774:Methylphenidate; D013148:Spironolactone; D011374:Progesterone; D004958:Estradiol; D010672:Phenytoin; D011239:Prednisolone; D005032:Ethylestrenol; D013974:Thyroxine; D010634:Phenobarbital